Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
Comparative Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- University of Padova
- Target Recruit Count
- 11206
- Registration Number
- NCT04304430
- Locations
- 🇮🇹
University Hospital of Padova, Padova, Italy
Dapagliflozin at Discharge on Hospital Heart Failure Readmission
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Emory University
- Target Recruit Count
- 105
- Registration Number
- NCT04249778
- Locations
- 🇺🇸
Temple University, Philadelphia, Pennsylvania, United States
🇺🇸Tulane University, New Orleans, Louisiana, United States
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)
- Conditions
- Interventions
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Kinderkrankenhaus auf der Bult
- Target Recruit Count
- 2
- Registration Number
- NCT04234867
- Locations
- 🇩🇪
Kinder- und Jugendkrankenhaus AUF DER BULT, Hanover, Lower Saxony, Germany
Replication of the DECLARE Diabetes Trial in Healthcare Claims
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 49790
- Registration Number
- NCT04215523
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
Dapagliflozin Efficacy and Action in PCOS
- First Posted Date
- 2019-12-30
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 165
- Registration Number
- NCT04213677
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
The Effects of SGLTi on Diabetic Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 30
- Registration Number
- NCT04200586
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
A Phase 2b Diabetic Kidney Disease Study
- Conditions
- Interventions
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 609
- Registration Number
- NCT04170543
- Locations
- 🇵🇪
Research Site, Piura, Peru
Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2019-11-04
- Target Recruit Count
- 1080
- Registration Number
- NCT04149067
- Locations
- 🇪🇸
Cristóbal Morales Portillo, Sevilla, Andalucía, Spain
Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04014192
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Effects of Hypoglycemic Drugs on Testosterone Levels in Type 2 Diabetes Patients
- Conditions
- Interventions
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Majianhua
- Target Recruit Count
- 74
- Registration Number
- NCT03982238
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.